The efficient growth inhibition induced by the MEK inhibitor U0126 in RD, colon carcinoma, prostate and melanoma cell lines clearly demonstrates that the MEK/ERK pathway is a pre-requisite for the aberrant growth of these cells. This evidence concerns the gene MAPK1 and melanoma.